by Robert Minicucci | Apr 22, 2020 | biopharma, cancer, clinical data, clinical research, Clinical Trials, Coronavirus, COVID-19, EMR, Oncology, Pharma, Uncategorized
Oncology clinical trials have been disrupted as hospitals dedicate more resources to care for COVID-19 patients. While the scope delays and suspensions are hard to assess, halting these trials can create devastating effects for patients in need of experimental...
by Robert Minicucci | Feb 12, 2020 | biopharma, cancer, clinical data, Clinical Trials, CROs, Pharma, primary data, RWD/RWE, Uncategorized
Concerns & Barriers Around Real-World Data Adoption At Inteliquet, we partner with Life Sciences and help reduce the barriers and time involved in clinical research. We recently conducted a survey to examine real-world data (RWD) adoption. Since the adoption is...
by Robert Minicucci | Jan 28, 2020 | clinical research, Clinical Trials, disruptive technology, healthcare, JP Morgan, Pharma, Uncategorized, WBL
For those of us in healthcare, the year begins with the JP Morgan Healthcare Conference. 2020 was no exception, so we wanted to know how Marie E. Lamont, a veteran of this conference, makes the most of her time. Here’s what she said: This year, I had the...
by Robert Minicucci | Dec 20, 2019 | ASH, cancer, clinical development strategy, clinical research, Clinical Trials, EMR, hematology, life sciences, Oncology, primary data, Uncategorized
The American Society of Hematology’s (ASH) 61st Annual Meeting & Exposition is the premier annual conference for malignant and non-malignant hematology. They work hard to bring new levels of collaboration and advocacy to find better treatments. Thank you to ASH...
by Robert Minicucci | Dec 16, 2019 | clinical research, CROs, FOCR, lung cancer, NSCLC, Oncology, patients, Pharma, RCTs, RWD/RWE, Uncategorized
What if real-world data (RWD) sources can increase the speed of getting therapies to market? Instead of waiting five years for a clinical trial to be designed, enrolled, and completed … what if we could do...
